Kai Sheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kai Sheng has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Hosni Cherif
Department of Surgery, Orthopaedic Research Laboratory, McGill University, Montreal, QC H3G 1A4, Canada
3 shared publications - Li Li
Department of Surgery, Division of Orthopaedics McGill University Montreal Quebec Canada
3 shared publications - Lisbet Haglund
Department of Surgery, Orthopaedic Research Laboratory, McGill University, Montreal, QC H3G 1A4, Canada
3 shared publications - Matthew Mannarino
McGill University Faculty of Medicine
2 shared publications - Peter Jarzem
Division of Orthopedics, Department of Surgery, McGill University, Montreal, Canada
2 shared publications - Christopher Coluni
McGill University, Department of Surgery, Montreal, Canada
1 shared publication
Latest Publications
- Open Access
- 26 December 2025
- Published by Springer Nature in European Spine Journal
- Vol. 35 (8) , 1-11
Technical insights and implications of thoracolumbar spine and neural tissue harvesting in recently deceased organ donors: a direct anterior approach integrated into multi-organ procurement protocols
Purpose: To present a novel anterior surgical technique for harvesting thoracolumbar spinal tissue from cadaveric organ donors. The approach aims to ensure biological viability of harvested spinal tissue, while maintaining full compatibility with routine multi-organ procurement protocols. By addressing the limited availability of anterior harvesting methods, this technique aims to expand opportunities for high-quality experimental and translational spine research. Methods: A direct anterior retroperitoneal approach was employed to harvest thoracolumbar spinal columns en bloc, including the spinal cord, dorsal root ganglia (DRGs), vertebral bodies, intervertebral discs, facet joints, and posterior elements. All extractions were performed within 1–2 h following aortic cross-clamping to minimize ischemic time. The surgical procedure included targeted osteotomies to preserve structural continuity, with intraoperative radiographic imaging performed to ensure alignment and suitability for subsequent research use. Tissue samples underwent same-day processing for experimental use, including viability assays to assess the cellular health of key structures. Results: This harvesting protocol was applied in over 340 cadaveric donors as part of a high-volume organ donation program. The mean harvesting time was approximately 30 min. In all cases, structural continuity of the anterior spinal column was preserved, with radiographic imaging confirming appropriate alignment and completeness of the harvested specimens. Cell viability assessments demonstrated excellent preservation of biologically active components, including viable disc and joint tissues, neural structures, and resident cell populations. The harvested tissues have been successfully used in a variety of research projects. Conclusion: This anterior spinal harvesting technique is a safe, efficient, and highly reproducible method that can be seamlessly integrated into standard multi-organ procurement workflows. It enables the acquisition of sterile, anatomically intact, and biologically viable spinal tissues from cadaveric organ donors without compromising donor reconstruction or surgical logistics. This approach substantially enhances the availability and quality of human spinal specimens for research and may serve as a useful model for tissue recovery in the field of spine science.
- 26 December 2025
- Published by Springer Nature in European Spine Journal
- Vol. 35 (8) , 1-11
Open AccessTechnical insights and implications of thoracolumbar spine and neural tissue harvesting in recently deceased organ donors: a direct anterior approach integrated into multi-organ procurement protocols
Purpose: To present a novel anterior surgical technique for harvesting thoracolumbar spinal tissue from cadaveric organ donors. The approach aims to ensure biological viability of harvested spinal tissue, while maintaining full compatibility with routine multi-organ procurement protocols. By addressing the limited availability of anterior harvesting methods, this technique aims to expand opportunities for high-quality experimental and translational spine research. Methods: A direct anterior retroperitoneal approach was employed to harvest thoracolumbar spinal columns en bloc, including the spinal cord, dorsal root ganglia (DRGs), vertebral bodies, intervertebral discs, facet joints, and posterior elements. All extractions were performed within 1–2 h following aortic cross-clamping to minimize ischemic time. The surgical procedure included targeted osteotomies to preserve structural continuity, with intraoperative radiographic imaging performed to ensure alignment and suitability for subsequent research use. Tissue samples underwent same-day processing for experimental use, including viability assays to assess the cellular health of key structures. Results: This harvesting protocol was applied in over 340 cadaveric donors as part of a high-volume organ donation program. The mean harvesting time was approximately 30 min. In all cases, structural continuity of the anterior spinal column was preserved, with radiographic imaging confirming appropriate alignment and completeness of the harvested specimens. Cell viability assessments demonstrated excellent preservation of biologically active components, including viable disc and joint tissues, neural structures, and resident cell populations. The harvested tissues have been successfully used in a variety of research projects. Conclusion: This anterior spinal harvesting technique is a safe, efficient, and highly reproducible method that can be seamlessly integrated into standard multi-organ procurement workflows. It enables the acquisition of sterile, anatomically intact, and biologically viable spinal tissues from cadaveric organ donors without compromising donor reconstruction or surgical logistics. This approach substantially enhances the availability and quality of human spinal specimens for research and may serve as a useful model for tissue recovery in the field of spine science.
- Open Access
- 8 December 2023
- Published by Springer Nature in Research Square
Causal relationship between gut microbiota and constipation: a two-sample Mendelian randomization study
Background As one of the most common gastrointestinal disorders, recent study has shown that dysfunction in the gut microbiota might lead to constipation. However, the causality between the gut microbiota and constipation is unclear. Methods Genome-Wide Association Studies (GWAS) used to obtain the summary-level data of constipation through IEU OpenGWAS database, and constipation was used as outcome. In addition, MiBioGen was used to gain the summary data of gut microbiota, including Ruminiclostridium 9, Intestinibacter, Anaerotruncus, Butyricimonas and Hungatella, which were used as exposure factors. Univariable Mendelian randomization (MR) analysis was used to evaluate the causality of gut microbiota on constipation. In briefly, Inverse-variance weighted (IVW) method was regarded as a main method to estimate the causality of gut microbiota and constipation, and supplemented by other four methods, including MR-egger, Weighted median, Simple mode and Weighted mode. Finally, funnel plot, heterogeneity test, horizontal pleiotropy test and leave-one-out test were used to evaluate the reliability of MR results. Results Ruminiclostridium 9 and Intestinibacter were causally associated with constipation and were the protective factors for constipation based on the MR analysis of IVW. The causal odds ratio (OR) values of Ruminiclostridium 9 and Intestinibacter were 0.75 (95% confidence interval (CI) 0.73–0.78; P < 0.001) and 0.89 (95% CI 0.86–0.93; P < 0.001) for constipation. Moreover, Anaerotruncus, Butyricimonas and Hungatella were also causally associated with constipation but were the risk factors for constipation. The OR values of Anaerotruncus, Butyricimonas and Hungatella were 1.08 (95% CI 1.02–1.13; P = 0.007), 1.07 (95% CI 1.01–1.13; P = 0.015), 1.03 (95% CI 1.00-1.06; P = 0.037) respectively. Furthermore, validation by funnel plot, heterogeneity test and horizontal pleiotropy test showed that MR results were reliable. Conclusion Ruminiclostridium 9, Intestinibacter, Anaerotruncus, Butyricimonas and Hungatella were identified as causalities of constipation, which provided a basis for understanding pathology of constipation and new insights into prevention and treatment.
- 8 December 2023
- Published by Springer Nature in Research Square
Open AccessCausal relationship between gut microbiota and constipation: a two-sample Mendelian randomization study
Background As one of the most common gastrointestinal disorders, recent study has shown that dysfunction in the gut microbiota might lead to constipation. However, the causality between the gut microbiota and constipation is unclear. Methods Genome-Wide Association Studies (GWAS) used to obtain the summary-level data of constipation through IEU OpenGWAS database, and constipation was used as outcome. In addition, MiBioGen was used to gain the summary data of gut microbiota, including Ruminiclostridium 9, Intestinibacter, Anaerotruncus, Butyricimonas and Hungatella, which were used as exposure factors. Univariable Mendelian randomization (MR) analysis was used to evaluate the causality of gut microbiota on constipation. In briefly, Inverse-variance weighted (IVW) method was regarded as a main method to estimate the causality of gut microbiota and constipation, and supplemented by other four methods, including MR-egger, Weighted median, Simple mode and Weighted mode. Finally, funnel plot, heterogeneity test, horizontal pleiotropy test and leave-one-out test were used to evaluate the reliability of MR results. Results Ruminiclostridium 9 and Intestinibacter were causally associated with constipation and were the protective factors for constipation based on the MR analysis of IVW. The causal odds ratio (OR) values of Ruminiclostridium 9 and Intestinibacter were 0.75 (95% confidence interval (CI) 0.73–0.78; P < 0.001) and 0.89 (95% CI 0.86–0.93; P < 0.001) for constipation. Moreover, Anaerotruncus, Butyricimonas and Hungatella were also causally associated with constipation but were the risk factors for constipation. The OR values of Anaerotruncus, Butyricimonas and Hungatella were 1.08 (95% CI 1.02–1.13; P = 0.007), 1.07 (95% CI 1.01–1.13; P = 0.015), 1.03 (95% CI 1.00-1.06; P = 0.037) respectively. Furthermore, validation by funnel plot, heterogeneity test and horizontal pleiotropy test showed that MR results were reliable. Conclusion Ruminiclostridium 9, Intestinibacter, Anaerotruncus, Butyricimonas and Hungatella were identified as causalities of constipation, which provided a basis for understanding pathology of constipation and new insights into prevention and treatment.
- Open Access
- 16 August 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (8) , 1257
Senolytic Combination Treatment Is More Potent Than Single Drugs in Reducing Inflammatory and Senescence Burden in Cells from Painful Degenerating IVDs
Background: Low back pain is a global health problem directly related to intervertebral disc (IVD) degeneration. Senolytic drugs (RG-7112 and o-Vanillin) target and remove senescent cells from IVDs in vitro, improving tissue homeostasis. One drawback of using a single senolytic agent is the failure to target multiple senescent antiapoptotic pathways. This study aimed to determine if combining the two senolytic drugs, o-Vanillin and RG-7112, could more efficiently remove senescent cells and reduce the release of inflammatory factors and pain mediators in cells from degenerating human IVDs than either drug alone. Methods: Preliminary data evaluating multiple concentrations of o-Vanillin and RG-7112 led to the selection of four treatment groups. Monolayer and pellet cultures of cells from painful degenerate IVDs were exposed to TLR-2/6 agonist. They were then treated with the senolytics o-Vanillin and RG7112 alone or combined. p16ink4a, Ki-67, caspase-3, inflammatory mediators, and neuronal sprouting were assessed. Results: Compared to the single treatments, the combination of o-Vanillin and RG-7112 significantly reduced the amount of senescent IVD cells, proinflammatory cytokines, and neurotrophic factors. Moreover, both single and combination treatments significantly reduced neuronal sprouting in rat adrenal pheochromocytoma (PC-12 cells). Conclusions: Combining o-Vanillin and RG-7112 greatly enhanced the effect of either senolytic alone. Together, these results support the potential of senolytics as a promising treatment for IVD-related low back pain.
- 16 August 2023
- Published by MDPI AG in Biomolecules
- Vol. 13 (8) , 1257
Open AccessSenolytic Combination Treatment Is More Potent Than Single Drugs in Reducing Inflammatory and Senescence Burden in Cells from Painful Degenerating IVDs
Background: Low back pain is a global health problem directly related to intervertebral disc (IVD) degeneration. Senolytic drugs (RG-7112 and o-Vanillin) target and remove senescent cells from IVDs in vitro, improving tissue homeostasis. One drawback of using a single senolytic agent is the failure to target multiple senescent antiapoptotic pathways. This study aimed to determine if combining the two senolytic drugs, o-Vanillin and RG-7112, could more efficiently remove senescent cells and reduce the release of inflammatory factors and pain mediators in cells from degenerating human IVDs than either drug alone. Methods: Preliminary data evaluating multiple concentrations of o-Vanillin and RG-7112 led to the selection of four treatment groups. Monolayer and pellet cultures of cells from painful degenerate IVDs were exposed to TLR-2/6 agonist. They were then treated with the senolytics o-Vanillin and RG7112 alone or combined. p16ink4a, Ki-67, caspase-3, inflammatory mediators, and neuronal sprouting were assessed. Results: Compared to the single treatments, the combination of o-Vanillin and RG-7112 significantly reduced the amount of senescent IVD cells, proinflammatory cytokines, and neurotrophic factors. Moreover, both single and combination treatments significantly reduced neuronal sprouting in rat adrenal pheochromocytoma (PC-12 cells). Conclusions: Combining o-Vanillin and RG-7112 greatly enhanced the effect of either senolytic alone. Together, these results support the potential of senolytics as a promising treatment for IVD-related low back pain.
- Open Access
o-Vanillin Modulates Cell Phenotype and Extracellular Vesicles of Human Mesenchymal Stem Cells and Intervertebral Disc Cells
Human mesenchymal stem cell (hMSC) and extracellular vesicle (EV) therapy is a promising treatment for discogenic low back pain (LBP). Although promising, major obstacles remain to be overcome. Cellular senescence reduces self-renewal and multipotent potentials, and the senescence-associated secretory phenotype creates an inflammatory environment negatively affecting tissue homeostasis. Reducing senescence could therefore improve regenerative approaches. Ortho-Vanillin (o-Vanillin) has senolytic activity and anti-inflammatory properties and could be a valuable supplement to MSC and EV therapy. Here, we used direct co-culture experiments to evaluate proteoglycan synthesis, inflammatory mediators, and senescent cells in the presence or absence of o-Vanillin. EV release and transfer between hMSCs and intervertebral disc cells (DCs) was examined, and the effect on hMSC differentiation and DC phenotype was evaluated in the presence and absence of o-Vanillin. This study demonstrates that o-Vanillin affects cell communication, enhances hMSC differentiation and improves DC phenotype. Co-cultures of DCs and hMSCs resulted in increased proteoglycan synthesis, a decreased number of senescent cells and decreased release of the cytokines IL6 and 8. Effects that were further enhanced by o-Vanillin. o-Vanillin profoundly increased EV release and/or uptake by hMSCs and DCs. DC markers were significantly upregulated in both cell types in response to conditioned media of o-Vanillin treated donor cells. Collectively, this study demonstrates that o-Vanillin affects hMSC and DC crosstalk and suggests that combining hMSCs and senolytic compounds may improve the outcome of cell supplementation and EV therapy for LBP.
Open Accesso-Vanillin Modulates Cell Phenotype and Extracellular Vesicles of Human Mesenchymal Stem Cells and Intervertebral Disc Cells
Human mesenchymal stem cell (hMSC) and extracellular vesicle (EV) therapy is a promising treatment for discogenic low back pain (LBP). Although promising, major obstacles remain to be overcome. Cellular senescence reduces self-renewal and multipotent potentials, and the senescence-associated secretory phenotype creates an inflammatory environment negatively affecting tissue homeostasis. Reducing senescence could therefore improve regenerative approaches. Ortho-Vanillin (o-Vanillin) has senolytic activity and anti-inflammatory properties and could be a valuable supplement to MSC and EV therapy. Here, we used direct co-culture experiments to evaluate proteoglycan synthesis, inflammatory mediators, and senescent cells in the presence or absence of o-Vanillin. EV release and transfer between hMSCs and intervertebral disc cells (DCs) was examined, and the effect on hMSC differentiation and DC phenotype was evaluated in the presence and absence of o-Vanillin. This study demonstrates that o-Vanillin affects cell communication, enhances hMSC differentiation and improves DC phenotype. Co-cultures of DCs and hMSCs resulted in increased proteoglycan synthesis, a decreased number of senescent cells and decreased release of the cytokines IL6 and 8. Effects that were further enhanced by o-Vanillin. o-Vanillin profoundly increased EV release and/or uptake by hMSCs and DCs. DC markers were significantly upregulated in both cell types in response to conditioned media of o-Vanillin treated donor cells. Collectively, this study demonstrates that o-Vanillin affects hMSC and DC crosstalk and suggests that combining hMSCs and senolytic compounds may improve the outcome of cell supplementation and EV therapy for LBP.